Introducing our new CEO: Dr Mark Street-Docherty
We are delighted to announce the appointment of Dr Mark Street-Docherty as Rosa Biotech’s new CEO.
Over an exciting past couple of years for the company, and under the leadership of former CEO, Dr Andy Boyce, Rosa’s team has demonstrated efficacy of its disruptive diagnostics platform, Pandra, in its first clinical indications. Mark now joins Rosa at the perfect time to lead us through the next stage of our growth and accelerate our journey to the clinic.
Mark is an exceptional leader with over a decade of experience in the life sciences industry. As a seasoned commercial executive in the in vitro diagnostics sector, he has extensive experience developing, manufacturing and successfully bringing innovative products into the clinical market and growing a global footprint.
Mark brings with him a number of years of experience as CEO leading the award-winning VC backed Elucigene Diagnostics business, in which he was responsible for leading the international growth and subsequent successful sale and merger to the Yourgene Health Group in 2019. He also supports a number of other UK life sciences businesses, including GenoME Diagnostics and MicrosensDx.
As well as his commercial expertise, Mark holds a PhD in Molecular Immunology and Mammalian Cell Biology from the University of Sheffield, and an Executive MBA.
Mark will now spearhead the development of our first in vitro diagnostic test in our lead indication, non-alcoholic fatty liver disease (NAFLD), a chronic liver disorder that affects millions of patients globally.
“I am really excited to be joining the Rosa team at this pivotal time as the Pandra platform pivots into the regulatory and commercial phases of its first diagnosis application,” Mark said.
Mark’s expertise is perfectly suited to the challenge of bringing Pandra to the clinic, and we are thrilled to have him on board!
We would also like to thank Andy for his commitment and leadership of Rosa during the last 3 years, particularly against a backdrop of challenges, and wish him every success for the future.